5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Paysign, Inc. (NASDAQ:PAYS), a $160 million market cap player in the business services sector showing strong momentum with a 23% gain last week, disclosed the outcomes of its annual stockholders meeting held on May 7, 2025. According to InvestingPro analysis, the company maintains a GOOD financial health score while delivering 27% revenue growth. The meeting’s agenda included the election of Board of Directors members, advisory votes on executive compensation ("say-on-pay"), the frequency of future say-on-pay votes ("say-on-frequency"), and the ratification of the company’s independent auditor for the upcoming fiscal year.
During the meeting, all seven nominees for the Board of Directors were elected to serve until the 2026 annual meeting. The stockholders cast their votes as follows: Mark R. Newcomer received 31,893,563 votes for, Matthew Lanford had 31,143,686, Joan M. Herman got 31,429,244, Bruce A. Mina received 31,948,322, Jeffrey B. Newman had 31,370,228, Daniel R. Henry received 31,947,864, and Dennis L. Triplett got 31,859,748 votes for their election.
The say-on-pay proposal, which is a non-binding advisory vote on the compensation of Paysign’s named executive officers for the fiscal year 2025, was approved with 31,789,535 votes in favor.
Regarding the say-on-frequency proposal, stockholders favored holding the advisory vote on executive compensation every three years, with 21,528,943 votes for a triennial schedule. The Board of Directors has accepted this preference and will implement the advisory vote accordingly.
Lastly, Moss Adams LLP was ratified as the independent registered public accounting firm for Paysign for the fiscal year ending December 31, 2025, with an overwhelming majority of 33,059,382 votes in favor.
These results were reported in a Form 8-K filed with the Securities and Exchange Commission on May 13, 2025, and reflect the decisions made by Paysign’s stockholders concerning the governance and oversight of the company. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks.
In other recent news, Paysign Inc. reported its Q1 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.05 against a forecast of $0.01. The company’s revenue reached $18.6 million, exceeding the anticipated $15.11 million, marking a 41% increase year-over-year. Paysign’s net income rose significantly by 737% to $2.59 million, demonstrating efficient operational scaling. The company also highlighted its acquisition of Gamma Innovation, which has bolstered its position in the plasma donor engagement market. Paysign’s financial health remains strong with zero debt and $6.9 million in unrestricted cash. Looking ahead, the company has set a total revenue guidance of $72-74 million for 2025, with expectations of a 25% growth. Plasma revenue is anticipated to decline slightly, while pharmaceutical revenue is projected to grow by 135%. Paysign forecasts a net income of $6-7 million and adjusted EBITDA of $16-17 million for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.